2006
DOI: 10.1053/j.gastro.2006.09.016
|View full text |Cite
|
Sign up to set email alerts
|

Inhibition of Smad7 With a Specific Antisense Oligonucleotide Facilitates TGF-β1–Mediated Suppression of Colitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

4
166
0
3

Year Published

2007
2007
2023
2023

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 187 publications
(173 citation statements)
references
References 23 publications
4
166
0
3
Order By: Relevance
“…There was no increased risk of infection observed in the study group in the induction phase compared to the placebo group [76]. Most serious adverse events in the study group were related to hospitalization due to underlying CD.…”
Section: Oral Smad7 Antisense Oligonucleotide Mongersenmentioning
confidence: 79%
See 4 more Smart Citations
“…There was no increased risk of infection observed in the study group in the induction phase compared to the placebo group [76]. Most serious adverse events in the study group were related to hospitalization due to underlying CD.…”
Section: Oral Smad7 Antisense Oligonucleotide Mongersenmentioning
confidence: 79%
“…The rate of clinical response reached as high as 72% in the mongersen group, and was significantly higher than that in the placebo group [76]. Both clinical remission and clinical response were observed most frequently in the group receiving 160 mg daily [76].…”
Section: Oral Smad7 Antisense Oligonucleotide Mongersenmentioning
confidence: 84%
See 3 more Smart Citations